Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 28;14(13):3172.
doi: 10.3390/cancers14133172.

Effect of Antibacterial Prophylaxis on Febrile Neutropenic Episodes and Bacterial Bloodstream Infections in Dutch Pediatric Patients with Acute Myeloid Leukemia: A Two-Center Retrospective Study

Romy E Van Weelderen  1   2 , Kim Klein  1   2   3 , Bianca F Goemans  2 , Wim J E Tissing  2   4 , Tom F W Wolfs  2   3 , Gertjan J L Kaspers  1   2
Affiliations

Effect of Antibacterial Prophylaxis on Febrile Neutropenic Episodes and Bacterial Bloodstream Infections in Dutch Pediatric Patients with Acute Myeloid Leukemia: A Two-Center Retrospective Study

Romy E Van Weelderen et al. Cancers (Basel). .

Abstract

Bloodstream infections (BSIs), especially those caused by Gram-negative rods (GNR) and viridans group streptococci (VGS), are common and potentially life-threatening complications of pediatric acute myeloid leukemia (AML) treatment. Limited literature is available on prophylactic regimens. We retrospectively evaluated the effect of different antibacterial prophylaxis regimens on the incidence of febrile neutropenic (FN) episodes and bacterial BSIs. Medical records of children (0−18 years) diagnosed with de novo AML and treated at two Dutch centers from May 1998 to March 2021 were studied. Data were analyzed per chemotherapy course and consecutive neutropenic period. A total of 82 patients had 316 evaluable courses: 92 were given with single-agent ciprofloxacin, 138 with penicillin plus ciprofloxacin, and 51 with teicoplanin plus ciprofloxacin. The remaining 35 courses with various other prophylaxis regimens were not statistically compared. During courses with teicoplanin plus ciprofloxacin, significantly fewer FN episodes (43 vs. 90% and 75%; p < 0.0001) and bacterial BSIs (4 vs. 63% and 33%; p < 0.0001) occurred than with single-agent ciprofloxacin and penicillin plus ciprofloxacin, respectively. GNR and VGS BSIs did not occur with teicoplanin plus ciprofloxacin and no bacterial BSI-related pediatric intensive care unit (PICU) admissions were required, whereas, with single-agent ciprofloxacin and penicillin plus ciprofloxacin, GNR BSIs occurred in 8 and 1% (p = 0.004), VGS BSIs in 24 and 14% (p = 0.0005), and BSI-related PICU admissions were required in 8 and 2% of the courses (p = 0.029), respectively. Teicoplanin plus ciprofloxacin as antibacterial prophylaxis is associated with a lower incidence of FN episodes and bacterial BSIs. This may be a good prophylactic regimen for pediatric AML patients during treatment.

Keywords: Gram-negative rods; antibacterial prophylaxis; bloodstream infections; ciprofloxacin; febrile neutropenia; pediatric acute myeloid leukemia; teicoplanin; viridans group streptococci.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Reedijk A.M.J., Klein K., Coebergh J.W.W., Kremer L.C., Dinmohamed A.G., de Haas V., Versluijs A.B., Ossenkoppele G.J., Beverloo H.B., Pieters R., et al. Improved survival for children and young adolescents with acute myeloid leukemia: A Dutch study on incidence, survival and mortality. Leukemia. 2019;33:1349–1359. doi: 10.1038/s41375-018-0314-7. - DOI - PubMed
    1. De Moerloose B., Reedijk A., de Bock G.H., Lammens T., de Haas V., Denys B., Dedeken L., Heuvel-Eibrink M.M.V.D., Loo M.T., Uyttebroeck A., et al. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01. Pediatr. Blood Cancer. 2019;66:e27605. doi: 10.1002/pbc.27605. - DOI - PubMed
    1. Rasche M., Zimmermann M., Borschel L., Bourquin J.P., Dworzak M., Klingebiel T., Lehrnbecher T., Creutzig U., Klusmann J.-H., Reinhardt D. Successes and challenges in the treatment of pediatric acute myeloid leukemia: A retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018;32:2167–2177. doi: 10.1038/s41375-018-0071-7. - DOI - PMC - PubMed
    1. Creutzig U., Zimmermann M., Reinhardt D., Dworzak M., Stary J., Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J. Clin. Oncol. 2004;22:4384–4393. doi: 10.1200/JCO.2004.01.191. - DOI - PubMed
    1. Reinhardt D., Antoniou E., Waack K. Pediatric Acute Myeloid Leukemia-Past, Present, and Future. J. Clin. Med. 2022;11:504. doi: 10.3390/jcm11030504. - DOI - PMC - PubMed

LinkOut - more resources